Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

Trends in Decline of Antiretroviral Resistance among ARV-Experienced Patients in the HIV Outpatient Study: 1999-2008.

Buchacz K, Baker R, Ward DJ, Palella FJ, Chmiel JS, Young B, Yangco BG, Novak RM, Brooks JT.

AIDS Res Treat. 2012;2012:230290. doi: 10.1155/2012/230290. Epub 2012 Mar 14.

2.

Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome.

Tozzi V, Zaccarelli M, Bonfigli S, Lorenzini P, Liuzzi G, Trotta MP, Forbici F, Gori C, Bertoli A, Bellagamba R, Narciso P, Perno CF, Antinori A; Collaborative Group for Clinical Use of HIV Genotype Resistance Test..

Antivir Ther. 2006;11(5):553-60.

PMID:
16964822
3.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
4.

Antiretroviral treatment outcome following genotyping in Thai children who failed dual nucleoside reverse transcriptase inhibitors.

Bunupuradah T, Suntarattiwong P, Li A, Sirivichayakul S, Pancharoen C, Boonrak P, Puthanakit T, Kerr SJ, Ruxrungtham K, Chotpitayasunondh T, Hirschel B, Ananworanich J; HIV-NAT 013 Study Team..

Int J Infect Dis. 2010 Apr;14(4):e311-6. doi: 10.1016/j.ijid.2009.05.017. Epub 2009 Aug 21.

5.

Prevalence and pattern of drug resistance mutations among antiretroviral-treated HIV-1 patients with suboptimal virological response in Malaysia.

Tee KK, Kamarulzaman A, Ng KP.

Med Microbiol Immunol. 2006 Jun;195(2):107-12. Epub 2006 Jan 11.

PMID:
16404607
6.

The effect of number of mutations and of drug-class sparing on virological response to salvage genotype-guided antiretroviral therapy.

Ciancio BC, Trotta MP, Lorenzini P, Forbici F, Visco-Comandini U, Gori C, Bonfigli S, Bellocchi MC, Sette P, D'Arrigo R, Tozzi V, Zaccarelli M, Boumis E, Narciso P, Perno CF, Antinori A.

Antivir Ther. 2003 Dec;8(6):611-6.

PMID:
14760895
7.

Changes in the use of HIV antiretroviral resistance testing in a large cohort of U.S. patients, 1999 to 2006.

Buchacz K, Baker RK, Young B, Brooks JT; HIV Outpatient Study (HOPS) Investigators..

J Acquir Immune Defic Syndr. 2010 Apr;53(5):625-32. doi: 10.1097/QAI.0b013e3181bf1dd2.

PMID:
19841587
8.

Nine-year trends in clinically relevant reduced susceptibility of HIV-1 to antiretrovirals.

Sista P, Rinehart A, Wasikowski B, Winters B, Pattery T, Bacheler L.

J Clin Virol. 2009 Mar;44(3):190-4. doi: 10.1016/j.jcv.2008.12.005. Epub 2009 Jan 24.

PMID:
19168389
9.

Does GSS still maintain relevance on HAART outcome after the introduction of newest active antiretroviral drugs? 48 weeks results.

Ortu M, Vitiello P, Adorni F, Rossotti R, Di Vincenzo P, Vigano O, Galli M, Rusconi S.

Curr HIV Res. 2011 Dec 1;9(8):625-9.

PMID:
22211659
10.

Prevalence of complete resistance to at least two classes of antiretroviral drugs in treated HIV-1-infected patients: a French nationwide study.

Masquelier B, Costagliola D, Schmuck A, Cottalorda J, Schneider V, Izopet J, Calvez V, Descamps D, Poggi C, Brun-Vézinet F; ANRS resistance sudy group..

J Med Virol. 2005 Aug;76(4):441-6.

PMID:
15977249
11.

Trends in use of genotypic resistance testing and frequency of major drug resistance among antiretroviral-naive persons in the HIV Outpatient Study, 1999-2011.

Buchacz K, Young B, Palella FJ Jr, Armon C, Brooks JT; HIV Outpatient Study (HOPS) investigators.; HIV Outpatient Study HOPS investigators..

J Antimicrob Chemother. 2015 Aug;70(8):2337-46. doi: 10.1093/jac/dkv120. Epub 2015 May 15.

PMID:
25979729
12.

GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy.

Bossi P, Peytavin G, Ait-Mohand H, Delaugerre C, Ktorza N, Paris L, Bonmarchand M, Cacace R, David DJ, Simon A, Lamotte C, Marcelin AG, Calvez V, Bricaire F, Costagliola D, Katlama C.

HIV Med. 2004 Sep;5(5):352-9.

13.

Antiretroviral drug resistance in HIV-infected patients in Colombia.

DiazGranados CA, Mantilla M, Lenis W.

Int J Infect Dis. 2010 Apr;14(4):e298-303. doi: 10.1016/j.ijid.2009.05.006. Epub 2009 Aug 8.

14.

Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication.

Delaugerre C, Braun J, Charreau I, Delarue S, Nere ML, de Castro N, May T, Marchou B, Simon F, Molina JM, Aboulker JP; ANRS 138-EASIER study group..

HIV Med. 2012 Oct;13(9):517-25. doi: 10.1111/j.1468-1293.2012.01002.x. Epub 2012 Mar 14.

15.

Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.

Chetchotisakd P, Anunnatsiri S, Mootsikapun P, Kiertiburanakul S, Anekthananon T, Bowonwatanuwong C, Kowadisaiburana B, Supparatpinyo K, Ruxrungtham K; Study Team..

HIV Med. 2007 Nov;8(8):529-35.

16.

Combination antiretroviral therapy without a nucleoside reverse transcriptase inhibitor: experience from 334 patients in three cohorts.

Calmy A, Petoumenos K, Lewden C, Law M, Bocquentin F, Hesse K, Cooper D, Carr A, Bonnet F; Aquitaine Cohort, Australian HIV Observational Database and St Vincent's Hospital Cohort study groups..

HIV Med. 2007 Apr;8(3):171-80.

17.

Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.

Rodes B, García F, Gutierrez C, Martinez-Picado J, Aguilera A, Saumoy M, Vallejo A, Domingo P, Dalmau D, Ribas MA, Blanco JL, Pedreira J, Perez-Elias MJ, Leal M, de Mendoza C, Soriano V; Red de Investigación en SIDA..

J Med Virol. 2005 Sep;77(1):23-8.

PMID:
16032728
18.
19.

Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.

Balotta C, Berlusconi A, Pan A, Violin M, Riva C, Colombo MC, Gori A, Papagno L, Corvasce S, Mazzucchelli R, Facchi G, Velleca R, Saporetti G, Galli M, Rusconi S, Moroni M.

Antivir Ther. 2000 Mar;5(1):7-14.

PMID:
10846586
20.

Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients.

Kozal MJ, Hullsiek KH, Leduc R, Novak RM, MacArthur RD, Lawrence J, Baxter JD; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA)..

Antivir Ther. 2006;11(4):457-63.

PMID:
16856619

Supplemental Content

Support Center